CN115776891A - Stat降解剂和其用途 - Google Patents
Stat降解剂和其用途 Download PDFInfo
- Publication number
- CN115776891A CN115776891A CN202180032886.6A CN202180032886A CN115776891A CN 115776891 A CN115776891 A CN 115776891A CN 202180032886 A CN202180032886 A CN 202180032886A CN 115776891 A CN115776891 A CN 115776891A
- Authority
- CN
- China
- Prior art keywords
- ring
- nitrogen
- sulfur
- oxygen
- partially unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990555P | 2020-03-17 | 2020-03-17 | |
| US62/990,555 | 2020-03-17 | ||
| US202063088945P | 2020-10-07 | 2020-10-07 | |
| US63/088,945 | 2020-10-07 | ||
| US202063123335P | 2020-12-09 | 2020-12-09 | |
| US63/123,335 | 2020-12-09 | ||
| US202163159102P | 2021-03-10 | 2021-03-10 | |
| US63/159,102 | 2021-03-10 | ||
| PCT/US2021/022794 WO2021188696A1 (en) | 2020-03-17 | 2021-03-17 | Stat degraders and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115776891A true CN115776891A (zh) | 2023-03-10 |
Family
ID=77771311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180032886.6A Pending CN115776891A (zh) | 2020-03-17 | 2021-03-17 | Stat降解剂和其用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240016942A1 (https=) |
| EP (1) | EP4121055A4 (https=) |
| JP (1) | JP2023518422A (https=) |
| CN (1) | CN115776891A (https=) |
| AU (1) | AU2021238333A1 (https=) |
| CA (1) | CA3170503A1 (https=) |
| IL (1) | IL296334A (https=) |
| MX (1) | MX2022011437A (https=) |
| WO (1) | WO2021188696A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026007994A1 (zh) * | 2024-07-03 | 2026-01-08 | 正大天晴药业集团股份有限公司 | 膦酸化合物及其用途 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12570679B2 (en) | 2019-03-29 | 2026-03-10 | Regents Of The University Of Michigan | STAT3 protein degraders |
| CN120574283A (zh) | 2019-04-05 | 2025-09-02 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| CN115677831B (zh) * | 2021-07-22 | 2026-03-17 | 杭州和正医药有限公司 | 拟肽类stat降解药物、组合物及应用 |
| CA3239730A1 (en) * | 2021-12-11 | 2023-06-15 | Christopher De Savi | Stat3 degraders and uses thereof |
| CA3253876A1 (en) * | 2022-03-31 | 2023-10-05 | Recludix Pharma, Inc. | STAT MODULATORS AND THEIR USES |
| WO2024030628A1 (en) * | 2022-08-05 | 2024-02-08 | Kymera Therapeutics, Inc. | Deuterated stat3 degraders and uses thereof |
| WO2024173291A1 (en) * | 2023-02-13 | 2024-08-22 | Regents Of The University Of Michigan | Compounds and compositions as stat3 degraders and uses thereof |
| WO2024173298A1 (en) * | 2023-02-13 | 2024-08-22 | Regents Of The University Of Michigan | Compounds and compositions as stat3 degraders and uses thereof |
| EP4709370A2 (en) * | 2023-05-09 | 2026-03-18 | Recludix Pharma, Inc. | Stat degraders and uses thereof |
| WO2024238603A2 (en) * | 2023-05-15 | 2024-11-21 | Recludix Pharma, Inc. | Stat degraders and uses thereof |
| EP4731622A1 (en) * | 2023-06-20 | 2026-04-29 | Regents of the University of Michigan | Compounds and compositions as vhl ligands and stat3 degraders uses thereof |
| CN117024254B (zh) * | 2023-08-10 | 2025-09-09 | 浙江大学衢州研究院 | 一种多氟苯酚的合成方法 |
| WO2026020004A1 (en) * | 2024-07-19 | 2026-01-22 | Gilead Sciences, Inc. | Stat6 compounds |
| WO2026027675A1 (en) | 2024-07-31 | 2026-02-05 | Guerra Gonzalez Carmen | Triple combination for use in the treatmet of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060742A1 (en) * | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| WO2020198435A1 (en) * | 2019-03-26 | 2020-10-01 | The Regents Of The University Of Michigan | Small molecule degraders of stat3 |
| US12570679B2 (en) * | 2019-03-29 | 2026-03-10 | Regents Of The University Of Michigan | STAT3 protein degraders |
| CN120574283A (zh) * | 2019-04-05 | 2025-09-02 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
-
2021
- 2021-03-17 CA CA3170503A patent/CA3170503A1/en active Pending
- 2021-03-17 AU AU2021238333A patent/AU2021238333A1/en not_active Abandoned
- 2021-03-17 MX MX2022011437A patent/MX2022011437A/es unknown
- 2021-03-17 US US17/912,388 patent/US20240016942A1/en active Pending
- 2021-03-17 WO PCT/US2021/022794 patent/WO2021188696A1/en not_active Ceased
- 2021-03-17 EP EP21771947.5A patent/EP4121055A4/en not_active Withdrawn
- 2021-03-17 CN CN202180032886.6A patent/CN115776891A/zh active Pending
- 2021-03-17 JP JP2022556046A patent/JP2023518422A/ja active Pending
- 2021-03-17 IL IL296334A patent/IL296334A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026007994A1 (zh) * | 2024-07-03 | 2026-01-08 | 正大天晴药业集团股份有限公司 | 膦酸化合物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021188696A1 (en) | 2021-09-23 |
| AU2021238333A1 (en) | 2022-09-29 |
| EP4121055A4 (en) | 2024-04-24 |
| IL296334A (en) | 2022-11-01 |
| CA3170503A1 (en) | 2021-09-23 |
| EP4121055A1 (en) | 2023-01-25 |
| MX2022011437A (es) | 2022-10-03 |
| JP2023518422A (ja) | 2023-05-01 |
| US20240016942A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7716554B2 (ja) | Ｓｔａｔ分解剤およびそれらの使用 | |
| US11932624B2 (en) | MDM2 degraders and uses thereof | |
| CN115776891A (zh) | Stat降解剂和其用途 | |
| US20260042762A1 (en) | Mertk degraders and uses thereof | |
| WO2020264490A1 (en) | Irak degraders and uses thereof | |
| WO2020251971A1 (en) | Smarca degraders and uses thereof | |
| KR20220145325A (ko) | Irak 분해제 및 이의 용도 | |
| EP4401729A1 (en) | Bcl-xl degraders and uses thereof | |
| TW202237601A (zh) | 介白素-1受體相關激酶(irak)降解物及其用途 | |
| WO2022125804A1 (en) | Smarca degraders and uses thereof | |
| EP4405359A2 (en) | Mdm2 degraders and uses thereof | |
| US20240293423A1 (en) | Stat degraders and uses thereof | |
| KR20240111312A (ko) | Tyk2 분해제 및 이의 용도 | |
| CN116490069A (zh) | Stat降解剂和其用途 | |
| TW202416950A (zh) | 雜芳基甲醯胺及相關gpr84拮抗劑及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |